Unal M, Peyman G A
LSU Eye Center, Louisiana State University Health Sciences Center School of Medicine, New Orleans, USA.
Retina. 2000;20(1):69-75. doi: 10.1097/00006982-200001000-00013.
To investigate the toxicity of intravitreal plasminogen, urokinase, and their combination, and to evaluate their efficacy in the production of posterior vitreous detachment (PVD) in the rabbit eye.
Fifty-six albino New Zealand rabbits were examined before and after injection using the indirect ophthalmoscope, slit-lamp biomicroscopy, and electroretinography. Various concentrations of urokinase or recombinant plasminogen or a combination were injected intravitreally into the right eyes of four rabbits for each concentration. The left eyes of the animals served as controls and received 0.1 mL balanced salt solution. Group 1 was injected with pure urokinase (1,000, 5,000, or 10,000 IU); Group 2 with recombinant plasminogen (0.1, 0.4, 1.0, 2.0, 4.0, 8.0, or 16.0 caseinolytic units [CU]); and Group 3 with a combination of 1,000 IU urokinase (highest nontoxic dose) and nontoxic concentrations of plasminogen (0.1, 0.4, 1.0, or 2.0 CU). The animals were killed and the eyes enucleated 15 days after injection. Electron and light microscopy were performed.
A concentration of 1,000 IU of urokinase was found to be nontoxic to the retina. Plasminogen concentrations of 2.0 CU or less did not produce retinal toxicity, whereas 4.0, 8.0, and 16.0 CU of plasminogen caused minimal-to-severe inflammatory response in the vitreous without histologic or electroretinographic changes. Neither plasminogen nor urokinase alone was successful in producing PVD. The combination of 1,000 IU of urokinase and 1.0 to 2.0 CU of plasminogen was effective without causing retinal toxicity.
Posterior vitreous detachment can be produced in the rabbit eye using a combination of plasminogen and urokinase.
研究玻璃体内注射纤溶酶原、尿激酶及其联合用药的毒性,并评估它们在诱导兔眼玻璃体后脱离(PVD)中的疗效。
使用间接检眼镜、裂隙灯生物显微镜和视网膜电图对56只白化新西兰兔在注射前后进行检查。将不同浓度的尿激酶或重组纤溶酶原或两者联合用药,分别对每组4只兔的右眼进行玻璃体内注射。动物的左眼作为对照,注射0.1 mL平衡盐溶液。第1组注射纯尿激酶(1000、5000或10000 IU);第2组注射重组纤溶酶原(0.1、0.4、1.0、2.0、4.0、8.0或16.0酪蛋白溶解单位[CU]);第3组注射1000 IU尿激酶(最高无毒剂量)与无毒浓度的纤溶酶原(0.1、0.4、1.0或2.0 CU)的组合。注射后15天处死动物并摘除眼球,进行电子显微镜和光学显微镜检查。
发现1000 IU的尿激酶浓度对视网膜无毒。2.0 CU或更低浓度的纤溶酶原未产生视网膜毒性,而4.0、8.0和16.0 CU的纤溶酶原在玻璃体中引起了轻微至严重的炎症反应,但无组织学或视网膜电图改变。单独使用纤溶酶原或尿激酶均未能成功诱导PVD。1000 IU尿激酶与1.0至2.0 CU纤溶酶原的联合用药有效且未引起视网膜毒性。
使用纤溶酶原和尿激酶联合用药可在兔眼中诱导玻璃体后脱离。